DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/lxc64d/global_overactive) has announced the addition of the "Global Overactive Bladder Therapeutics Market 2014-2018" report to their offering.
One major trend emerging in this market is the increase in awareness about overactive bladder syndrome. It results in an increase in the consumption of medications, thereby, contributing to the growth of the market.
Overactive bladder is a urological condition associated with urination problems. The condition is characterized by bladder storage symptoms such as urgency, change in frequency of urination, nocturia, or urinary incontinence. It is also known as overactive bladder syndrome. Although it is not a life-threatening condition, it is often stigmatized and debilitating. Some of the important symptoms of overactive bladder are urinary urgency and incontinence.
The pathophysiology of overactive bladder is not characterized completely. The symptoms of overactive bladder can last for a lifetime or it can relapse and remit. The problem can be resolved through treatment. Overactive bladder can affect a person irrespective of the gender. The reason is the abnormal contraction of the urinary detrusor muscle of the bladder. In addition, overactive bladder can be related to neurological diseases such as Parkinson's disease and multiple sclerosis.
According to the report, the major driving factor of the market is the rise in the geriatric population suffering from various diseases, which are at risk of developing overactive bladder syndrome. This results in an increase in the consumption of drugs for overactive bladder, thereby, boosting growth.
Further, the report states that the difficulty in diagnosis is a major challenge to the growth of the market. It results in fewer treatment-seeking patients, which, in turn, restrains the growth of the market. The diagnosis is done through clinical examination and a series of diagnostic tests to rule out the possibilities of bladder cancer, urinary tract infection, and benign prostatic hyperplasia.
To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of overactive bladder, which include:
- Anti-muscarinic Agent
- Beta-3-Adrenergic Receptor Agonist
- Astellas Pharma
For more information visit http://www.researchandmarkets.com/research/lxc64d/global_overactive